Daraxonrasib (RMC-6236), an investigational RAS(ON) inhibitor, is generating major attention in metastatic pancreatic ductal adenocarcinoma (PDAC) after positive Phase 3 RASolute 302 trial results showed significant improvements in overall survival and progression-free survival compared with standard chemotherapy. The drug has received FDA breakthrough therapy and orphan drug designations for previously treated metastatic PDAC.
The results may be practice-changing, with outcomes reportedly two to three times better than current standard therapies for patients with RAS-mutated tumors. Questions remain about effectiveness in KRAS wild-type disease.
An FDA-authorized Expanded Access Program (EAP) is allowing select patients to receive the drug during regulatory review, but major logistical barriers remain. Physicians face delays of four to six weeks before treatment can begin due to institutional review board approvals, financial reviews, and patient-specific applications. Community oncology practices often lack the infrastructure needed to support the program, driving referrals to larger academic centers.
Daraxonrasib also introduces a different toxicity profile from chemotherapy, with severe rash emerging as a key side effect requiring dermatology support. Standard FDA approval is anticipated later in 2026, while future studies are already exploring frontline and combination treatment strategies.